about
Molecular testing to optimize therapeutic decision making in advanced colorectal cancerAdvances in targeted and immunobased therapies for colorectal cancer in the genomic eraRecent Advances in Chemotherapy and Surgery for Colorectal Liver MetastasesInforming materials: drugs as tools for exploring cancer mechanisms and pathways.Miniaturized Real-Time PCR on a Q3 System for Rapid KRAS GenotypingRole of Biologics in Colon Cancer: Still Not Clear.Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.High-throughput detection of clinically targetable alterations using next-generation sequencing.Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer.Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.Use of a High-Throughput Genotyping Platform (OncoMap) for RAS Mutational Analysis to Predict Cetuximab Efficacy in Patients with Metastatic Colorectal Cancer.ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer.Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2.Patient-derived xenografts as tools in pharmaceutical development.Advances in Biomarkers: Going Beyond the Carcinoembryonic Antigen.Clinicopathological Associations of K-RAS and N-RAS Mutations in Indonesian Colorectal Cancer Cohort.Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing.Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.Differential Radiographic Appearance of BRAF V600E-Mutant Metastatic Colorectal Cancer in Patients Matched by Primary Tumor Location.Prognostic factors after resection of colorectal liver metastases following preoperative second-line chemotherapy: Impact of RAS mutations.The pattern of KRAS mutations in metastatic colorectal cancer: a retrospective audit from Sri Lanka.BRAF-mutated metastatic colorectal cancer between past and future.Heterogeneity of driver genes and therapeutic implications in colorectal cancer.Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review.Mechanistic regulation of epithelial-to-mesenchymal transition through RAS signaling pathway and therapeutic implications in human cancer.EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer.
P2860
Q26749012-7387074E-382A-4687-87B4-6810E60FE7EDQ26751344-BCC160D6-DD29-4BB1-95F9-D3A6C458066EQ28067408-08560896-4C09-4C64-8AFE-18A2797CA9B0Q30402161-76503DBC-1F77-4DB9-B8FF-0D57677B0EA1Q33649652-D388FF1E-10D5-4A17-A2A6-0705FC599CCDQ33756787-4CED0936-80ED-4573-AFB7-A280AA7F81D6Q36264188-51674084-5C8D-4383-B3B2-BB93559B9F6AQ36345358-98E0176A-1B47-45E1-93EF-47174623ECC2Q36472281-1C3732FC-656E-4C68-9527-434EB90373D3Q36472959-2E43CAAE-D18A-4FDD-AE4B-CEEAE4050BE3Q37525272-A3AC8741-13C6-405C-A0BE-37E40730610BQ37606696-CA2CF907-7561-4E48-AB96-7B9BC0416EE3Q37725589-628AE4B3-5FF4-4ED7-9C69-B3EBC4AC838DQ38582586-D88EAFD7-5FAA-4218-AB41-8CBF1E49E914Q38732336-BEB0F860-4C45-4E78-94A2-2E77CCBD7F5AQ38943220-5645C9C1-4E82-452A-9485-17EBEDCFA14AQ39065326-F257DE74-99C8-4C22-B729-1A6CD2B9AAECQ40100583-4F95663F-9E79-41CE-A933-CCCD0FCEEC2EQ40197692-9B51C804-1FC1-4608-9340-0E3815F54828Q40428222-625C0EC3-FE79-44A4-8A44-50DA5DF142E9Q40674654-FFD2B503-40E5-4629-92CA-1937D53D0722Q41361628-097265DD-772A-43D5-BAB3-6768E8C30E0CQ43099398-70AA4FE1-FD1A-4CEF-8712-78CACD63C184Q43549198-C98D4ED3-7DF0-42FD-86BC-E06D66FF94EEQ47134024-E5D1E814-BD79-4237-A3BE-9FCB043AFE5FQ50057521-830BB626-B687-4364-9B59-AAB06304A6ADQ51307822-C25A359C-DF85-4F22-8058-71C7F174F298
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Expanded RAS: refining the patient population
@ast
Expanded RAS: refining the patient population
@en
type
label
Expanded RAS: refining the patient population
@ast
Expanded RAS: refining the patient population
@en
prefLabel
Expanded RAS: refining the patient population
@ast
Expanded RAS: refining the patient population
@en
P2860
P356
P1476
Expanded RAS: refining the patient population
@en
P2093
Chloe E Atreya
Ryan B Corcoran
P2860
P304
P356
10.1200/JCO.2014.58.9325
P407
P50
P577
2015-01-12T00:00:00Z